For nearly all of the 20th century, biologists gained considerable insights into the fundamental principles of cellular dynamics by examining select modules of biochemical processes. This form of analysis provides detailed information about the workings of the examined pathways. However, any attempt to alter the normal function of bacteria (perhaps for industrial or medicinal goals) requires a detailed global understanding of cellular mechanisms. The reductionist mode of analysis cannot provide the required information for developing the needed perspective on the complex interactions of biochemical pathways. Thankfully, the increasing availability of microbial genomic, transcriptomic, proteomic and other high-throughput data permits system-level analyses of microbiology. During the past two decades, systems biologists have developed constraint-based genome-scale models (GSM) of metabolism for a variety of pathogens. These models are important tools for assessing the metabolic capabilities of various genotypes. Simultaneously, new computational methods have been developed that use these network reconstructions to answer an array of important immunological questions. The objective of this article is to briefly review some of the uses of GSMs for studying bacterial metabolism under different conditions and to discuss how the calculated solutions can be used for rational design of drugs.
INTRODUCTION
Revolutionary advances in high-throughput bioanalytical technologies have made it possible to shift the focus of immunological and bacteriological studies away from a limited number of high priority processes to those where the pathogen, the infected host cell, the patient or a multi-scale combination of all three are modeled as a 'system'. These forms of analyses are the primary focus of the new field of systems biology. Systems biology is a broad term used to describe the study of the transient interactions of a large number of disparate biochemical processes with the aim of garnering new insights into how organisms respond to different stimuli.
For pharmaceutical purposes, systems biology examinations of bacterial metabolism as well as host-pathogen interactions can provide new information about the infection process and lead to identification of critical pathways which might be targeted for drug development. The genomes of a large number of immunologically important bacteria have been sequenced and their rank is continually growing. Use of this and other 'omic' (e.g. proteomic, transcriptomic, metabolomic, fluxomic) data permits examination of the complicated networks of biochemical reactions that govern the behavior of these pathogens. To this end, genome-scale computational models (GSM) of bacterial metabolisms Dr Ali Navid is a Staff Scientist in Biosciences and Biotechnology Division of Lawrence Livermore National Laboratory. serve as critical tools for translating experimental measurements into a mathematical format that can be studied and manipulated.
GSMs have been developed for a variety of different bacteria, ranging in pathogenicity from that of Porphyromonas gingivalis [1] , a human oral pathogen largely responsible for periodontitis, to Helicobacter pylori [2] that causes gastritis, ulcers and in some cases gastric cancer, to finally United States Center for Disease Control and prevention (CDC) category A pathogens such as Yersinia pestis, the causative agent of bubonic plague [3] . Table 1 lists some of the pathogenic bacteria that have been modeled. For a more complete list and access to some of these models, the reader is encouraged to visit the Biochemical Genetic and Genomic (BiGG) database [4] (bigg.ucsd.edu).
To date, system-level metabolic reconstructions have been used to: (i) examine the metabolic capabilities of the organisms, (ii) scrutinize the robustness of metabolic networks to internal and external perturbations, (iii) study the bacteria's network properties (e.g. [5] [6] [7] ), (iv) guide metabolic engineering projects and (v) explore metabolic interactions in heterogeneous cellular communities. As the scope of biological processes that are included in GSMs grows, the models will play a critical role in design of immunological experiments as well as research studies in the emergent fields of metabolic engineering and synthetic biology.
MODEL DEVELOPMENT
The process of developing genome-scale metabolic models has been extensively reviewed [8] [9] [10] . Therefore, since the scope of this article is to review the various pharmaceutical and immunological uses of system-level models, only an abstract review of the process is provided. For the most comprehensive and detailed protocol of how to develop a GSM the reader is directed to see the article by Thiele and Palsson [11] .
Genome-scale reconstruction of metabolic networks involves a series of steps:
(i) Development of a draft genome-scale metabolic reconstruction. The annotated genome provides the modeler with a list of enzymes that could be present in the bacteria. By using databases such as KEGG [12] , and MetaCyc [13] each enzyme can be linked to a set of biochemical reactions. (ii) Curation of the reconstructed network using the information that is available in the literature. (iii) Translation of the reconstructed network into a mathematical format that can be solved by computational methods. (iv) Simulation and network augmentation (e.g. metabolic network gap filling) in line with experimental data and observed phenotypic characteristics of the organism.
The most widely used method for system-level modeling of cellular metabolism is called flux balance analysis (FBA) [14, 15] . FBA is a constraint-based methodology that is based on four central assumptions:
(i) Mass is conserved.
(ii) Internal and external metabolic fluxes have a finite capacity. (iii) When compared to that of cellular growth, the time constants associated with metabolic transients are very fast and thus the system is considered to be at steady state. (iv) Metabolic activity of a cell is driven solely to optimize a physiological goal. The objective of choice for most FBA models is production of cellular biomass (i.e. growth).
Due to the steady state assumption, the mass balance equation can be written as: where S is a matrix containing the stoichiometry of the metabolic reactions, v is the vector of metabolic reaction rates and b is the vector of demand for a metabolite in line with optimization of the model's objective function. Since there are a lot more unknown reaction rates in S than linear independent mass balance equations, the stoichiometric matrix is rank deficient and the problem is highly underdetermined. The problem can still be solved by using linear programming to calculate a feasible flux vector which would optimize an objective function. However, the solution provided by FBA is not unique and alternate metabolic flux patterns can also provide the same maximum value of a model's objective function. The popularity and success of FBA methodology stems from the fact that while FBA models incorporate all known metabolic reactions and account for all the associated genes and proteins, they circumvent the primary obstacle to development of dynamic GSMs, namely dearth of kinetic parameters for in vivo enzymatic catalyses. Another advantage of FBA is that because it is a constraint-based approach, when compared to other methodologies, it is comparatively easier to incorporate diverse types of high-throughput data into the models. By incorporating new data in to the models, the accuracies of their predictions can be improved. Overall, the process of model development is an evolutionary process that can continue for many years. For example, the GSM of Escherichia coli has been continually improved since it was first published in early 1990s [14, [16] [17] [18] [19] [20] [21] [22] [23] [24] and surely with the advent of new algorithms and new analytical tools the process of curation will continue.
Recently a number of tools for automated generation, simulation and analysis of draft metabolic models have been developed [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . These programs primarily deal with linear optimization problems. At this point it should be noted that while methodologies using linear optimization are by far the most widely used algorithms for assessing a metabolic network's capabilities, for some complex problems other optimization methods such as those based on quadratic programming (e.g. minimization of metabolic adjustments (MOMA), a method for predicting metabolic properties of mutant bacterial strains [35] ) and mixed-integer programming (e.g. methods for identifying alternate optimal flux distributions [36] ) should be used.
MODEL APPLICATIONS Improving genome annotation
One of the critical steps in the process of GSM development is identifying metabolic reactions that are either missing or incorrectly included in the draft network reconstruction. The missing metabolic reactions are usually identified when there is experimental evidence supporting the activity of a metabolic pathway in an organism but the annotated genome does not include the necessary enzymes. An exhaustive search of the literature is critical for development of a high-quality FBA model. Especially for bacteria and parasites, it is important to check the literature and ensure that a pathogen has not augmented its metabolism to extract a needed metabolite from the host or the transmission vector. For example, some pathogenic bacteria such as Y. pestis after diverging from their free-living progenitors have inactivated a significant fraction of their metabolic enzymes as they adapt to their new parasitic life style [37] .
An incomplete metabolic pathway is the main cause of inaccurate model predictions. Therefore, a number of different methods have been developed to identify candidate genes that encode the missing enzymes. In order to identify a gene that might encode a missing functionality, tools of comparative genomics are used to examine a variety of genetic characteristics such as: clustering of genes on a chromosome, phylogenetic profiling, gene and protein fusion events, and shared regulatory sites [38] . In some organisms, the catalyzing protein might be an analog of a known enzyme. Analogs have the same functionality as known proteins but due to different evolutionary paths are not genetically or structurally similar to recognized enzymes. Such novel enzymes can be identified by analyzing anticorrelations in instances when genes are found across various species [39] . The PathoLogic program, a module in the Pathway Tools software that is developed by SRI international includes an algorithm that utilizes a Bayesian method and joins homology and pathway-based evidence to identify candidate genes for missing functions in pathways [13, 40] .
Identification of essential genes
Once the FBA models have been curated and validated using experimental data, simple algorithms can be written to identify the genes and proteins that are essential for bacterial growth. During the process of model development, it is important to develop a database or table which keeps track of the geneprotein-reaction (GPR) associations (Table 2) . To test whether inactivation of a gene hinders bacterial growth, the GPR table is used to identify all reactions that are linked to the target gene. Next, the fluxes for these reactions are set to zero and the model is tested to see if under these constraints the bacteria can still produce biomass at a rate greater than a threshold value. If the theoretical gene deletion inhibits cellular growth then the gene is identified as an essential gene (ES) (Figure 1) .
For system-level analyses, one by one each member of the set of genes (G) that is included in the reconstructed network is computationally knocked out. For this form of analysis it is very important to account for: (i) Presence of genes that encode isozymes that could catalyze the same reactions (e.g. products of fbp and glpX in Table 2 ). Since FBA models do not account for the differences in the enzymatic efficiencies of various proteins, as long as two proteins have the same functionality, they are assumed to have a similar proficiency in catalyzing reactions. Presence of isozymes means that associated genes are not essential. (ii) Protein complexes. Unless experimental data indicate otherwise, all proteins that form a protein complex are deemed essential for the proper function of that enzyme. Thus in cases where an enzyme complex is found to be essential for cellular growth, all genes that encode the constituent subunits are also identified as essential.
The results of gene essentiality analyses are very dependent on the growth environment. Therefore, when comparing model predictions with experimental data it is very important to ensure that the in silico simulation environment matches the experimental setting. Comparisons of model predictions of essentiality with experimental data have shown that models can have accuracies higher than 80% and that some of the predicted essential genes are known drug targets [41] [42] [43] . System-level analyses have shown that in cases where models inaccurately identify genes as either essential or non-essential, the primary causes of error are incomplete knowledge of: (i) function of the genes, (ii) roles of the genes in the overall cellular metabolism, (iii) metabolic pathways (i.e. presence or absence of alternate pathways) and (iv) incorrect objective functions [44, 45] .
Another method that can be used to ascertain the essentiality of specific metabolic reactions is called the flux variability analysis (FVA). As previously mentioned, the flux values calculated by FBA models are not unique. There are numerous degenerate solutions that can also lead to a maximum value of the objective function. FVA is a method devised to examine the range of fluxes that each reaction can have while the objective function is at its maximum value [46] . Active reactions that exhibit zero variability in their fluxes are essential for growth of the bacteria under simulated environmental conditions. Thus comparing the flux of a reaction under two different conditions could provide invaluable information with regards to the changes in the overall metabolic state of the bacteria. Note that (i) some reactions can be catalyzed by the product of more than one gene like the reaction that can catalyzed by Fbp and GlpX.
(ii) the products of some genes (like AspC) can catalyze more than one reaction.
The identified essential genes constitute an ideal set of targets for development of antimicrobial drugs. A large number of pathogen reconstructions have been used to determine the essentiality of genes for bacterial growth. Coupling the results of these analyses with those derived from the available human GSMs [47, 48] ensures that the essential enzymes that ultimately might be used for drug development are only essential for the bacteria and not for the survival of the host. Additionally, economic considerations compel drug companies to develop drugs for long-term treatment of chronic ailments instead of developing remedies such as antibiotics that are needed sporadically [49] . Given this limitation, in order to make development of antimicrobial drugs cost-effective, it is 'preferable' that new antimicrobial drugs have broad-spectrum capability so that they can be used for treatment of a variety of different diseases. Comparing the essentiality of genes among different bacteria is an ideal method for identifying targets for broad-spectrum therapeutics. For example, an analysis of gene essentiality among 13 different strains of Staphylococcus aureus identified 44 single enzymes that were essential for all of them [50] . With ever increasing availability of genome sequences of bacteria and advent of web-based tools such as Model Seed [25, 26] which allow for rapid development of many different FBA models, the tedious search for targets of broad-spectrum therapeutics could soon become more tractable.
Synthetic lethal mutations
The possibility that a drug might not fully inhibit a targeted physiological functionality and the increased prevalence of bacteria developing drug resistance via single gene mutations make it necessary to consider devising therapeutic regimes that would inhibit multiple targets. For example, a majority of antibacterial agents that target single enzymes in pathogens (e.g. novobiocin, sulfonamides and rifampin) are prone to high-level resistance stemming from single-step mutations [51] . Due to prevalence of such phenomena, above mentioned drugs are usually used in combination with other drugs. In support of such measures, it has been proposed that partial inhibition of multiple proteins might actually be more efficient at achieving medicinal goals than complete inhibition of a single target [52] .
Another reason for developing multi-targeting therapeutic regimens is shortage of new drug targets. A recent system-level analysis of Salmonella enterica metabolism during infection revealed that nearly all of the essential enzymes in this organism are unsuitable for use as novel broad-spectrum drug targets. This is due to the discovery that the identified essential enzymes are either (i) absent from other key pathogens, (ii) have high sequence identities similar to important human enzymes or (iii) belong to metabolic pathways that are already targeted by antimicrobial agents [53] . Based on all these factors we can deduce that targeting multiple proteins would be beneficial in that: (i) it would eliminate the burden of Figure 1 : A schematic diagram of the steps for identifying essential genes using GSMs. G represents the set of all the metabolic genes that are included in the GSM. g i represents a single gene (g i 2 G) and the value of i ranges from one to number of elements in G. R g i represents the set of reactions that are associated with g i . r j represents reaction j in R g i and f r j represents the flux of reaction r j . To identify the set of essential genes (ES), the GPR file is used to identify the R g i for each g i . Next, the fluxes for all of the reactions that are part of R gi are set to zero. Using the model, the effect of these reaction deletions is simulated. If growth is inhibited g i is an essential gene, else it is a non-essential gene (NE ¼G À ES). The process is repeated for all the genes in G.
developing drugs that are absolute inhibitors and (ii) it will expand the fraction of bacterial proteome that can be targeted for drug development [54] .
Given the complexity of the metabolic networks, the task of identifying multiple drug targets that would be deleterious for bacterial growth is not trivial. However, in silico analysis of bacterial networks might be an ideal method for identification of such gene groupings, particularly if we limit our search to combinations of two genes. This is because one of the routine uses of GSMs involves identification of synthetic lethal mutations (SLMs) [3, 50, 55, 56] . SLM refers to a situation when simultaneous deletions of a couple of non-lethal genes prove to be fatal.
Identification of SLMs in bacteria using GSMs is very similar to the process used to identify essential genes. However, for identifying SLMs only the non-essential genes (NE) need to be tested. Simple algorithms can be developed to systematically identify (using the GPR table) and incapacitate a grouping of reactions that are associated with a tandem of genes. As with single gene essentiality analysis, if the theoretical deletion of a duo of inessential genes halts cellular growth, then that pair is identified as an SLM.
Each identified SLM provides us with a duo of drug targets that need to be inhibited concurrently in order to halt bacterial growth. To date majority of the system-level studies have limited their analyses to deletions of gene couples and have not tried toidentify more complex combinations. The primary reason for this is that examination of more involved mixtures would be computationally taxing. However, in one case, high performance computing has been used to simulate the effects of gene deletions for combinations of up to four genes [57] .
Metabolite-centric analyses
Another method for examining the outcome of perturbations to the fluxes of multiple reactions in a network is to shift the focus of analyses away from reaction-centered searches to one where the essentiality of each metabolite in a network is examined [58] . The metabolite-centric method examines the global effects of varying the combined fluxes of reactions that either produce or consume each member of the metabolome. Please note that as a result of the steady state constraint that is imposed on FBA models, the sum value of fluxes for anabolic and catabolic reactions for most metabolites are equal to one another. Another benefit of using this form of analysis comes from the fact that the identified drug target is a metabolite (rather than genes and proteins) and hence its structure can be used as a starting point for the design of antibacterial agents [59] .
The metabolite-centric method has been used to study the metabolism of E. coli, H. Pylori, Mycobacterium tuberculosis and S. aureus and the combined results have been used to identify a number of drug targets. By examining the role of these targets in the human metabolic network, the list of essential bacterial targets was reduced through elimination of those compounds that are also necessary for human survival. In the end chorismate was identified as a possible drug target for treatment of all four bacteria [59] . A survey of literature validated this result by showing that a number of different studies have previously used chorismate as a possible drug target for treatment of these pathogens.
FUTURE DIRECTIONS Drugs that target bacterial virulence
The increasing trend of finding antibiotic resistant strains of deadly bacteria has led some to advocate a paradigm shift in choice of targets for antimicrobial therapies [60] [61] [62] . They reason that because of bacteria's rapid development of drug resistance and the ease with which resistance is transferred among different organisms [63] , new anti-bacterial treatments need to target new pathways and possess novel structures [62] . It has been suggested that this can be done by shifting the focus of our drug target searches away from those pathways that are essential for microbial growth to pathways that are conditionally essential, particularly those that are critical for the progression of infections [61, 62] . Accordingly, in the near future, system-level models of metabolism could be used to identify genes and enzymes that are vital for production of virulence factors such as siderophores or quorum sensing signaling molecules.
Metabolic engineering for nutritional and pharmaceutical purposes
A number of different studies have utilized GSMs to design bacterial strains with either novel or improved capabilities to produce metabolites of interest. Bacterial strains have been generated that overproduce different metabolites such as amino acids [64] [65] [66] , lycopene [67, 68] , lactate [69] , succinate [70, 71] and ethanol [72] . The models have been primarily used to examine the metabolic network of an organism and identify beneficial gene deletions that would divert the metabolic flux toward the production of a desired metabolite. The results of these metabolic engineering efforts have been very promising and ultimately could improve the industrial production of a variety of biochemical compounds ranging from nutritional supplements to biofuels.
Metabolic engineering can also be used to modify the metabolism of organisms that produce antimicrobial compounds. Bacillus subtilis is a very wellcharacterized organism that has the capability to produce more than two dozen antibiotics with very different structures [73] . To date two different models for this organism have been developed [74, 75] , but the models have not yet been used to improve the production of antibiotics.
Another organism that produces antibiotics and has been modeled is Streptomyces coelicolor [76] . The GSM for S. coelicolor was used to assess its potential for producing the polyketide antibiotic actinorhodin. Additionally, it was used to examine the effects of reduced activity of glycolytic enzyme phosphofructokinase on production of secondary metabolites and antibiotics [77] .
To data a number of different computational programs have been developed to aid in the process of strain optimization [64, 78] . FBA models so far have not been fully exploited for improved production of antibiotics. However, predictions from GSM models that are currently under development and can integrate various forms of high-throughput data and correctly follow the rules of thermodynamics will be a lot more accurate. These improvements should entice more drug developers to use these computational tools for the purpose of engineering drug producing bacterial strains.
Modeling host-pathogen interactions
The ultimate goal of any immunological study is to examine the interaction of a pathogen with the host immune system and to devise a mean by which the latter can overcome the former. Absence of proper experimental models, particularly those that would mimic in vivo conditions, has limited our ability to fully examine the infection process. Theoretical studies of host-pathogen interactions could partially remedy this shortcoming.
Until recently, it was not possible to develop GSMs for multi-cellular organisms and properly assign metabolic processes to specific organs. The global model of human metabolism [47] is based on the annotated human genome and accounts for nearly all of the possible reactions that can occur in human cells. Still one cannot use this model to study metabolism in a specific tissue such as liver or kidney. However, recent developments of new algorithms which allow for integration of gene expression data into FBA models [79] [80] [81] and make the networks more context-specific have made it possible to develop models for specific human cells. Bordbar et al. have used these advances to develop the first GSM of human alveolar macrophage and then successfully modeled the metabolic interaction between the macrophage and M. tuberculosis [82] . Given that experimental observations have shown that the infection process for a number of bacteria is accompanied by changes in microbial metabolism, advances such as those outlined above could greatly facilitate our efforts to understand the infection process.
CONCLUSIONS
A system-level understanding of bacterial metabolism is critical for assessing any organism's weaknesses and exploiting that knowledge for development of new therapeutics. However, global analysis of cellular metabolism is not a trivial task. The roster of active reactions that at any moment govern the metabolism of a bacterium depend on a variety of different genetic and epigenetic factors. Even when we know the list of active enzymes, the metabolic networks at any moment are composed of hundreds to thousands of different reactions working in a cooperative manner to achieve a variety of different tasks.
We can attempt to conduct system-level studies primarily due to the ready availability of various forms of omics data. The bioinformatic data can be used to mathematically model, analyze, and predict bacterial behavior with increasing accuracy. GSMs have been used for a variety of purposes including identification of enzymes that are critical for bacterial propagation. By comparing the results from a variety of different pathogens we can compile a list of enzymes that are essential for growth in a variety of different bacteria. These enzymes can then be scrutinized for their role in human metabolism and ultimately any enzyme that is only critical for bacterial survival might be targeted for development of broad-spectrum therapeutic agents.
As new algorithms are developed for integration of new biological data into GSMs and methodologies for developing models of specific mammalian tissues mature, our capacity to accurately predict host-pathogen metabolic interactions improves. Eventual inclusion of regulatory pathway as well as detailed modeling of transcription and translation processes could expand the scope of system-level models beyond metabolism. These developments could in the near future make in silico system-level analysis a transformative technology that would greatly facilitate the process of developing antimicrobial agents.
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Key Points
GSMs of metabolism are an essential tool for system-level analysis of microbial biology. Identifying genes that are essential for bacterial growth and SLMs can provide us with a list of targets for novel drug development. As the scope of biochemical processes that are included in GSMs increases, the accuracy of model predictions will improve. In silico modeling of host^pathogen can greatly expand the current frontiers of immunology.
